B. Dekkers, Martijn Bakker, K. V. D. van der Elst, M. Sturkenboom, Anette Veringa, L. Span, J. Alffenaar
2016.5.7Current Fungal Infection Reports
tlooto Summary
The most recent findings on pharmacokinetics and pharmacodynamics of posaconazole in the setting of prophylaxis and treatment of fungal infections are highlighted and the challenges associated with TDM are referred to.
Abstract
Posaconazole is a second-generation triazole agent with a potent and broad antifungal activity. In addition to the oral suspension, a delayed-release tablet and intravenous formulation with improved pharmacokinetic properties have been introduced recently. Due to the large interindividual and intraindividual variation in bioavailability and drug-drug interactions, therapeutic drug monitoring (TDM) is advised to ensure adequate exposure and improve clinical response for posaconazole. Here, we highlight and discuss the most recent findings on pharmacokinetics and pharmacodynamics of posaconazole in the setting of prophylaxis and treatment of fungal infections and refer to the challenges associated with TDM of posaconazole.
Citation format
DEKKERS, B., et al. Therapeutic drug monitoring of posaconazole: An update. Current Fungal Infection Reports, 2016, 10: 51–61.